Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience.

Abstract

BACKGROUND:

The Stanford group has reported excellent results with the Stanford V regimen for patients with bulky and/or advanced Hodgkin lymphoma (HL). However, Gobbi reported markedly inferior failure-free survival (FFS) comparing Stanford V to other regimens but included major deviations from the original program. We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data.

PATIENTS AND METHODS:

From June 1995 to May 2002, 126 patients with either locally extensive or advanced HL were treated with the 12-week Stanford V chemotherapy program followed by 36-Gy involved-field radiotherapy to sites initially > or =5 cm and/or to macroscopic splenic disease. Overall, 26% had stage IV disease and 20% had international prognostic score (IPS) > or =4. Overall survival (OS), disease-specific survival, progression-free survival (PFS), FFS, and freedom from second relapse (FF2R) were determined.

RESULTS:

The 5- and 7-year OS were 90% and 88%, respectively. The 5-year FFS was 78%. IPS > or =4 was a significant independent predictor of worse OS and PFS. The FF2R was 64% at 3 years.

CONCLUSION:

Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL.

• Authors: S M Edwards-Bennett, L M Jacks, C H Moskowitz, E J Wu, Z Zhang, A Noy, C S Portlock, D J Straus, A D Zelenetz, J Yahalom
• Journal: Annals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 21 Issue 3 Pg. 574-581 (Mar 2010) ISSN: 1569-8041 [Electronic] England
• PMID: 19759185 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Topics

• Adolescent
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Combined Modality Therapy
• Disease-Free Survival
• Female
• Hodgkin Disease (drug therapy, radiotherapy, therapy)
• Humans
• Male
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy, radiotherapy, therapy)
• Neoplasm Staging
• Retrospective Studies
• Salvage Therapy
• Survival Rate
• Treatment Outcome
• Young Adult